DDInter1836 DDInter336
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Torasemide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Celecoxib
Torasemide {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Torasemide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Celecoxib
Torasemide {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Torasemide {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is associated with {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Torasemide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Torasemide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is downregulated by {v} (Disease) colon cancer
colon cancer {u} (Disease) is palliated by {v} (Compound) Celecoxib
Torasemide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is palliated by {v} (Compound) Celecoxib
Torasemide {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) interacts with {v} (Gene) PDPK1
PDPK1 {u} (Gene) is bound by {v} (Compound) Celecoxib
Torasemide {u} (Compound) upregulates {v} (Gene) CEBPD
CEBPD {u} (Gene) is downregulated by {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is palliated by {v} (Compound) Celecoxib
Torasemide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Celecoxib (Compound)
Torasemide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Torasemide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Celecoxib (Compound)
Torasemide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)
Torasemide (Compound) treats hypertension (Disease) and hypertension (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Torasemide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)
Torasemide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is downregulated by colon cancer (Disease) and colon cancer (Disease) is palliated by Celecoxib (Compound)
Torasemide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is palliated by Celecoxib (Compound)
Torasemide (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) interacts with PDPK1 (Gene) and PDPK1 (Gene) is bound by Celecoxib (Compound)
Torasemide (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is downregulated by rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Celecoxib (Compound)